Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

OTLK has been the subject of a number of other reports. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research decreased their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Outlook Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $28.07.

Outlook Therapeutics Trading Up 1.8 %

NASDAQ:OTLK opened at $2.23 on Friday. The stock’s 50-day moving average is $2.70 and its 200-day moving average is $5.35. Outlook Therapeutics has a 1-year low of $0.87 and a 1-year high of $12.85. The stock has a market cap of $55.54 million, a P/E ratio of -0.25 and a beta of 0.53.

Outlook Therapeutics (NASDAQ:OTLK) last posted its earnings results on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. As a group, equities analysts forecast that Outlook Therapeutics will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in OTLK. Christensen King & Associates Investment Services Inc. bought a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $55,000. AQR Capital Management LLC acquired a new stake in Outlook Therapeutics in the second quarter worth $75,000. Barclays PLC increased its stake in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Outlook Therapeutics during the third quarter valued at about $199,000. Finally, Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics during the 2nd quarter worth about $232,000. 11.20% of the stock is owned by institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.